Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Condition:   Hematologic Neoplasms Interventions:   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Sirolimus;   Drug: Filgrastim;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Total Body Irradiation (TBI) Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials